Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Holding ASRT?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.04Last Year’s EPS
$0.11Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 11, 2024
|% Change Since: -4.32%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Neutral
The call reflected a mixed performance with steady sales of ROLVEDON and a strong financial position offset by declining INDOCIN sales and lingering external pressures. Strategic leadership changes and exploration of new growth opportunities provide an optimistic outlook, though pricing pressures remain a concern.Company Guidance
During the Assertio Holdings Q3 2024 earnings call, the company maintained its guidance range due to factors such as the transition from INDOCIN to ROLVEDON and the competitive landscape. Total product sales for the quarter were $28.7 million, a slight decline from $30.7 million in Q2, with ROLVEDON sales holding steady at $15 million, contributing to about one-third market share in its served markets. The gross margin improved to 74%, up from 71% in the previous quarter, while SG&A expenses decreased to $16.7 million from $18.4 million. The company reported a GAAP net loss of $2.9 million, while adjusted EBITDA increased to $5.3 million. Assertio ended the quarter with a total cash position of $88.6 million and debt unchanged at $40 million. The company remains focused on stabilizing its business and exploring growth opportunities, particularly in the oncology market with ROLVEDON, while managing the lifecycle and market share of its legacy assets.Steady ROLVEDON Performance
ROLVEDON sales were stable at $15 million in Q3, maintaining a 33% market share in the community oncology clinic space.
Strong Financial Position
Total cash at the end of the quarter was $88.6 million, with debt remaining unchanged at $40 million.
Improved Gross Margin
Reported gross margin improved to 74% in Q3 compared to 71% in Q2 due to lower inventory step-up amortization and write-downs.
Strategic Leadership Changes
Heather Mason appointed as Chairwoman of the Board, and David Stark joined the Board, bringing extensive industry and legal expertise.
New Growth Opportunities
Continued focus on expanding ROLVEDON into hospital markets and exploring label expansion opportunities.
---
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 11, 2024 | $0.92 | $0.85 | -7.61% |
| Aug 07, 2024 | $1.23 | $1.08 | -12.20% |
| May 06, 2024 | $1.22 | $1.11 | -9.02% |
| Mar 11, 2024 | $0.93 | $1.01 | +8.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Assertio Therapeutics Inc (ASRT) report earnings?
Assertio Therapeutics Inc (ASRT) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Assertio Therapeutics Inc (ASRT) earnings time?
Assertio Therapeutics Inc (ASRT) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.04.
---